OncoMatch/Clinical Trials/NCT06491680
Cardiotoxicity in Breast Cancer Patients
Is NCT06491680 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Dapagliflozin 10mg Tab for breast cancer.
Treatment: Dapagliflozin 10mg Tab — The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug. Aim of the study: Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity. The main questions it aims to answer are: 1. Does the drug lower the cardiotoxicity which induced by anthracyclines? 2. What medical problems do participants have when taking dapagliflozin drug? Treatment 1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg/m2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg/m2 with cyclophosphamide 600 mg as a combination. 2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Prior therapy
Cannot have received: anthracycline-containing regimen
Previous anthracycline-containing regimens
Cannot have received: cardiotoxic chemotherapy
any cardiotoxic chemotherapy regimens
Lab requirements
Kidney function
egfr > 30 ml/minute per 1.73 m2
Cardiac function
lvef > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify